Journal articles: 'SCR free'

1

Al-Ababneh, Nedal. "Crosstalk in misaligned free space optical interconnects: modelling and simulation." International Journal of Electrical and Computer Engineering (IJECE) 9, no. 3 (June 1, 2019): 1620. http://dx.doi.org/10.11591/ijece.v9i3.pp1620-1629.

Full text

Abstract:

<p>We introduce convenient model and an optimization scheme to optimize the signal-to-crosstalk ratio (SCR) in a free space optical interconnects (FSOIs) system that uses microlenses with finite circular apertures. In this model, we consider both the stray light crosstalk and the crosstalk due to the diffraction at the microlens apertures to evaluate the SCR. Using cylindrical form of Collins diffraction integral and the Laguerre–Gaussian (LG) beam model, we derive an approximate closed form formula for the optical field of a multimode LG beam propagating through circular apertured FSOIs by expanding the hard edge circular aperture function of the microlens in terms of complex Gaussian functions. The analyses indicate that the size of the detector is an important factor to optimize the SCR for both the apertured and the unapertured misaligned FSOIs system. The effect of higher order mode of the laser source on the SCR is also considered. </p>

APA, Harvard, Vancouver, ISO, and other styles

2

Laycock, Douglas. "The Remnants of Free Exercise." Supreme Court Review 1990 (January 1990): 1–68. http://dx.doi.org/10.1086/scr.1990.3109655.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Al-ababneh, Nedal. "Crosstalk Modeling in Lens Based Free Space Optical Interconnects Systems with Circular Symmetry." Modern Applied Science 12, no. 6 (May 28, 2018): 112. http://dx.doi.org/10.5539/mas.v12n6p112.

Full text

Abstract:

We introduce convenient model and an optimization scheme to optimize the signal-to-crosstalk ratio (SCR) in a free space optical interconnects (FSOIs) system that uses microlenses with finite circular apertures. In this model, we consider both the stray light crosstalk and the crosstalk due to the diffraction at the microlens apertures to evaluate the SCR. Using cylindrical form of Collins diffraction integral and the Laguerre–Gaussian (LG) beam model, we derive an approximate closed form formula for the optical field of a multimode LG beam propagating through circular apertured FSOIs by expanding the hard edge circular aperture function of the microlens in terms of complex Gaussian functions. The analyses indicate that the size of the detector is an important factor to optimize the SCR for both the apertured and the unapertured misaligned FSOIs system. The effect of higher order mode of the laser source on the SCR is also considered.

APA, Harvard, Vancouver, ISO, and other styles

4

Liu, Fudong, Yunbo Yu, and Hong He. "Environmentally-benign catalysts for the selective catalytic reduction of NOxfrom diesel engines: structure–activity relationship and reaction mechanism aspects." Chem. Commun. 50, no. 62 (2014): 8445–63. http://dx.doi.org/10.1039/c4cc01098a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Grupp, Stephan A., Julie W. Stern, Nancy Bunin, Cheryl Nancarrow, Amy A. Ross, Mark Mogul, Roberta Adams, et al. "Tandem High-Dose Therapy in Rapid Sequence for Children With High-Risk Neuroblastoma." Journal of Clinical Oncology 18, no. 13 (July 1, 2000): 2567–75. http://dx.doi.org/10.1200/jco.2000.18.13.2567.

Full text

Abstract:

PURPOSE: Advances in chemotherapy and supportive care have slowly improved survival rates for patients with high-risk neuroblastoma. The focus of many of these chemotherapeutic advances has been dose intensification. In this phase II trial involving children with advanced neuroblastoma, we used a program of induction chemotherapy followed by tandem high-dose, myeloablative treatments (high-dose therapy) with stem-cell rescue (HDT/SCR) in rapid sequence. PATIENTS AND METHODS: Patients underwent induction chemotherapy during which peripheral-blood stem and progenitor cells were collected and local control measures undertaken. Patients then received tandem courses of HDT/SCR, 4 to 6 weeks apart. Thirty-nine patients (age 1 to 12 years) were assessable, and 70 cycles of HDT/SCR were completed. RESULTS: Pheresis was possible in the case of all patients, despite their young ages, with an average of 7.2 × 106 CD34+ cells/kg available to support each cycle. Engraftment was rapid; median time to neutrophil engraftment was 11 days. Four patients who completed the first HDT course did not complete the second, and there were three deaths due to toxicity. With a median follow-up of 22 months (from diagnosis), 26 of 39 patients remained event-free. The 3-year event-free survival rate for these patients was 58%. CONCLUSION: A tandem HDT/SCR regimen for high-risk neuroblastoma is a feasible treatment strategy for children and may improve disease-free survival.

APA, Harvard, Vancouver, ISO, and other styles

6

Zhu, Yongjun, Bingbing Chen, Rongrong Zhao, Qi Zhao, Hermann Gies, Feng-Shou Xiao, Dirk De Vos, et al. "Fe-doped Beta zeolite from organotemplate-free synthesis for NH3-SCR of NOx." Catalysis Science & Technology 6, no. 17 (2016): 6581–92. http://dx.doi.org/10.1039/c6cy00231e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wright, R. George. "A Rationale from J. S. Mill for the Free Speech Clause." Supreme Court Review 1985 (January 1985): 149–78. http://dx.doi.org/10.1086/scr.1985.3109499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sullivan, Kathleen M. "Cheap Spirits, Cigarettes, and Free Speech: The Implications of 44 Liquormart." Supreme Court Review 1996 (January 1996): 123–61. http://dx.doi.org/10.1086/scr.1996.3109728.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Stone, Geoffrey R. "The Origins of the "Bad Tendency" Test: Free Speech in Wartime." Supreme Court Review 2002 (January 2002): 411–53. http://dx.doi.org/10.1086/scr.2002.3109722.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Dankeaw, Apiwat, Fabrizio Gualandris, Rafael Hubert Silva, Roberto Scipioni, Kent Kammer Hansen, Bussarin Ksapabutr, Vincenzo Esposito, and Debora Marani. "Highly porous Ce–W–TiO2 free-standing electrospun catalytic membranes for efficient de-NOxvia ammonia selective catalytic reduction." Environmental Science: Nano 6, no. 1 (2019): 94–104. http://dx.doi.org/10.1039/c8en01046c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Ming-Dou Ker and Kuo-Chun Hsu. "Latchup-free esd protection design with complementary substrate-triggered scr devices." IEEE Journal of Solid-State Circuits 38, no. 8 (August 2003): 1380–92. http://dx.doi.org/10.1109/jssc.2003.814434.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Song, Song, Guangjun Wu, Weili Dai, Naijia Guan, and Landong Li. "Al-free Fe-beta as a robust catalyst for selective reduction of nitric oxide by ammonia." Catalysis Science & Technology 6, no. 23 (2016): 8325–35. http://dx.doi.org/10.1039/c6cy02124g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Sentenac, D., A. N. Shalaginov, A. Fera, and W. H. de Jeu. "On the instrumental resolution in X-ray reflectivity experiments." Journal of Applied Crystallography 33, no. 1 (February 1, 2000): 130–36. http://dx.doi.org/10.1107/s0021889899014272.

Full text

Abstract:

A general method to describe the instrumental resolution function for grazing-angle X-ray scattering experiments is presented. A resolution function {\scr R} is introduced as the Gaussian joint-distribution function of the (interdependent) random deviationq′ associated with the wavevector transferq. Useful expressions for the mean square values ofq′ are derived for some common scattering geometries, such as rocking scans, and scans out of the plane of incidence. The mean square values related to the incident beam dispersion and the detector acceptance angles are included in the treatment of {\scr R}. As an example, {\scr R} is incorporated in the calculation of the diffuse scattering from free-standing smectic films within the framework of the first Born approximation and the main resolution effects are discussed.

APA, Harvard, Vancouver, ISO, and other styles

14

Atallah, Atallah A., Osama M. Morsy, Wael Abbas, and El-Sayed G. Khater. "Microstructural, Physicochemical, Microbiological, and Organoleptic Characteristics of Sugar- and Fat-Free Ice Cream from Buffalo Milk." Foods 11, no. 3 (February 8, 2022): 490. http://dx.doi.org/10.3390/foods11030490.

Full text

Abstract:

Ice cream is a popular dessert product across the world. Structure, body, taste, and odor properties are created by adding non-milk ingredients and milk ingredients. The main aim of the study is to decrease the caloric value of ice cream by using sugar and fat replacements. Ice cream treatments were investigated based on microstructural, chemical, physical, microbiological, sensory, and calorific values. Four different ice creams were used (control ice cream (SC1), ice cream with stevia (SC2), ice cream with sucralose (SC3), and ice cream with sorbitol (SC4)). The chemical properties in all treatments of ice cream were significantly recorded (p < 0.05). The highest sucrose and fat levels were detected in the SC1 treatment compared with the other treatments (p < 0.05). The lowest fat and sugar amounts were observed in the SC2, SC3, and SC4 treatments (p < 0.05). The highest viscosity, overrun, and hardness values (p < 0.05) were detected in the control ice cream. Total aerobic mesophilic bacterial counts were not significantly recorded between different ice cream treatments (p < 0.05). The sensory scores were not significantly affected by sweeteners and bulk agents in the different treatments. The highest calorific value was calculated in the SC1 samples (p < 0.05). On the other hand, the lowest calorific value was calculated in SC2, followed by the SC3 and SC4 treatments. In scanning electron microscopy (SEM), the gel exhibited a homogeneous structure with a fine network within the SC2, SC3, and SC4 treatments, as it contained a cohesive structure with small-sized pores.

APA, Harvard, Vancouver, ISO, and other styles

15

Köhler, Thomas, and Michael Prinzleve. "Is Forgetting of Dreams due to Repression? Experimental Investigations Using Free Associations." Swiss Journal of Psychology 66, no. 1 (March 2007): 33–40. http://dx.doi.org/10.1024/1421-0185.66.1.33.

Full text

Abstract:

This study investigated whether forgetting of dream material is due to repression. Under this assumption, free associations starting from forgotten elements are expected to encounter successively growing resistance. In Experiment 1, 25 participants brought along notes of dreams and were asked to freely associate to five elements from their own dreams and five stimuli from someone else’s dreams. One week later, they were tested for recognition of sequences of their dreams. Afterwards they produced free associations to five elements they had remembered and to five elements not identified (Experiment 2). Skin conductance responses (SCR) and perceived unpleasantness were recorded. Results of Experiment 1 were in line with previous findings from our laboratory: Associations starting from own dream material provoke greater SCRs. Results of Experiment 2 were: In comparison to recognised dream material, unrecognised elements elicited associations accompanied by greater activation. During associations to the latter stimuli, increase of SCR was more frequent, and unpleasant feelings were reported more often. Our findings are in line with Freud’s assumptions on forgetting of dreams.

APA, Harvard, Vancouver, ISO, and other styles

16

Lv, Nangui, Chenhu Sun, Xueqin Wang, Chan Wang, Yuanyuan Yue, and Xiaojun Bao. "Understanding the superior NH₃-SCR activity of CHA zeolite synthesized via template-free interzeolite transformation." Inorganic Chemistry Frontiers 9, no. 6 (2022): 1300–1312. http://dx.doi.org/10.1039/d1qi01414e.

Full text

Abstract:

A highly active NH3-SCR catalyst (Cu-CHAUSY) derived from CHA-type zeolite (CHAUSY) that is synthesized via template-free interzeolite transformation from ultra-stable Y (USY) with specific silicon and aluminum configurations.

APA, Harvard, Vancouver, ISO, and other styles

17

Kapoor, Prashant, Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, David Dingli, Suzanne R. Hayman, Francis K. Buadi, et al. "Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma." Blood 120, no. 21 (November 16, 2012): 1988. http://dx.doi.org/10.1182/blood.v120.21.1988.1988.

Full text

Abstract:

Abstract Abstract 1988 Background With the utilization of novel agent-based combination therapies and autologous stem-cell transplantation (ASCT) in multiple myeloma (MM), the rigorous response category of stringent complete remission (sCR) in the international uniform response criteria is increasingly becoming attainable. In addition to the standard criteria for complete remission (CR), sCR requires normalization of the free light chain ratio and disappearance of clonal cells as determined by the marrow immunofluorescence or immunohistochemistry. We have previously validated the new response category of sCR created in by the International Myeloma Working Group and demonstrated that sCR represents a deeper level of response, translating into a superior OS. Herein we report the survival outcomes of patients attaining sCR or standard CR, from a 2-year landmark after ASCT in a cohort of patients with extended follow-up. Additionally, we report the outcome of patients who remained in sCR for at least 6 months (sustained-sCR) after ASCT. Patients and Methods Maximal response rates of four hundred and forty-five consecutive patients who underwent ASCT within 12 months of diagnosis of MM were determined. The population achieving varying degrees of complete remission (n=237) is the focus of this study. We performed a landmark analysis 2 years after ASCT to ensure that all the patients attaining at least CR had sufficient time to reach the response levels being studied. Patients were categorized as having sustained sCR (sus-sCR) if the duration of sCR was at least 6 months. Overall survival (OS) was estimated by the Kaplan Meier method and the survival curves were compared by log-rank test. Results The median follow-up of the entire cohort was seventy-seven months (95% CI: 73–82 months). The sCR rate after ASCT was 24% (n=109). Median time to progression (TTP) of patients attaining sCR was 50 months from ASCT, and median overall survival (OS) is not reached, in contrast to those attaining standard CR (n=37, TTP=20 months, OS=81 months) or near CR/nCR (n=91; TTP= 19 months, OS=60 months, p<0.0001 for both TTP and OS). OS of patients surviving at least 2 years from ASCT (Figure 1a) continued to remain superior for those attaining sCR (n=105, median: not reached) versus 70 months for the CR group (n=32; p=0.004). Among patients achieving sCR (n=109), OS of patients with sus-sCR (n= 75) at 6 months from ASCT is not reached (5-year OS=91%, 7-year OS=86%) versus median OS of 66 months (5-year OS=49%, 7-year OS=37%; p<0.0001) for those who had non-sustained-sCR (n=34) after ASCT (Figure 1b). Conclusion In our landmark analysis of patients with MM who survived at least 2 years from ASCT, those attaining sCR have a markedly superior outcome compared to those attaining standard CR. However, among patients attaining sCR, those with sustained sCR of 6 months or greater had the best outcome. Myeloma trials reporting response rates should identify patients achieving sCR and CR separately owing to markedly disparate outcomes of the two categories. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

18

Chen, Shen Li, and Chun Ju Lin. "Evaluation of ESD/LU Reliabilities by Different SCR Layout Types in a 0.35μm 3.3V CMOS Process." Advanced Materials Research 779-780 (September 2013): 1124–29. http://dx.doi.org/10.4028/www.scientific.net/amr.779-780.1124.

Full text

Abstract:

This paper aimed at the evaluation of layout dependence on ESD/LU reliabilities in the 0.35μm 3.3V low-voltage triggered silicon-controlled-rectifier (LVTSCR) DUTs. In this work, the parameter of channel L in a pMOS and the parameter S of an SCR are varied to study the influence on trigger voltage (Vt1), holding voltage (Vh) and secondary breakdown current (It2), respectively. Eventually, it can be found that the layout illustration of type-2 has a higher It2than that of type-1, i.e., the ratio of (It2)type-2/(It2)type-1> 3 among all the LVTpSCRs. Meanwhile, the holding voltage of all SCR devices are latch-up free while operated at 3.3V. Therefore, the type-2 layouts of SCR devices are so excellent structure in the ESD/LU reliability considerations for this 0.35μm 3.3V CMOS process.

APA, Harvard, Vancouver, ISO, and other styles

19

Zhao, Zhenchao, Rui Yu, Chuan Shi, Hermann Gies, Feng-Shou Xiao, Dirk De Vos, Toshiyuki Yokoi, et al. "Rare-earth ion exchanged Cu-SSZ-13 zeolite from organotemplate-free synthesis with enhanced hydrothermal stability in NH3-SCR of NOx." Catalysis Science & Technology 9, no. 1 (2019): 241–51. http://dx.doi.org/10.1039/c8cy02033g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Zhou, Feng, Guimei Yang, Feng Tang, Yan Zhang, Wenqing Yang, Liting Xue, Ping Chen, and Renhong Tang. "Abstract 5642: Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancers." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5642. http://dx.doi.org/10.1158/1538-7445.am2022-5642.

Full text

Abstract:

Abstract The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival and overall survival in HR positive and HER2-negative breast cancer in combination either with letrozole or fulvestrant. However, resistance to the CDK4/6 inhibition inevitably develops. Preclinical models and clinical transcriptome specimen analysis disclosed that abnormal activation of Cyclin E/CDK2 due to CCNE gene amplification was one of the major reasons to CDK4/6 inhibition resistance. And inhibition of CDK2 either by gene knockdown of CCNE or by pharmaceutic approach rescued the sensitivity of resistant tumor cells to CDK4/6 inhibition. To overcome the resistance, a novel and selective CDK2/4/6 inhibitor, SCR-8079 was developed. In biochemical assay, SCR-8079 was demonstrated high potency on inhibiting CDK2/4/6 with IC50 of 3 nM, 1 nM and 2 nM, respectively. And SCR-8079 showed good selectivity over CDK1/9 isoforms (>60 selectivity folds). SCR-8079 demonstrated closed inhibitory activities both on CDK4/6 sensitive and resistant lines. In MCF-7, a breast cancer cell line sensitive to PAL, SCR-8079 potently inhibited Rb phosphorylation (IC50, 53 nM) and cell proliferation (IC50, 28 nM). Meanwhile, SCR-8079 showed high potency on inhibiting on the growth of OVCAR3, an ovarian cancer cell line with elevated CDK2 activation and resistance to PAL. SCR-8079 inhibited Rb phosphorylation (IC50, 41 nM) and cell proliferation (IC50, 21 nM). In order to further mimic CDK4/6 resistance, a PAL resistant line (MCF-7R) was generated via induction of MCF-7 by gradient increased PAL. SCR-8079 potently inhibited MCF-7R cells growth (IC50, 3 nM) but PAL didn’t (IC50 >1 µM). Moreover, SCR-8079 showed high potency on growth inhibition in a broad of breast cancer cell lines, including HR-positive, Her2-positive and triple negative lines. SCR-8079 displayed good oral bioavailability in multiple pre-clinical species and robust anti-tumor activities both in OVCAR3 and MCF7 xenograft models. In summary, SCR-8079 is a selective CDK2/4/6 inhibitor, which overcomes the CCNE-mediated resistance to CDK4/6 inhibition. Broad anti-tumor activity suggests SCR-8079 central role in breast cancer treatment. Citation Format: Feng Zhou, Guimei Yang, Feng Tang, Yan Zhang, Wenqing Yang, Liting Xue, Ping Chen, Renhong Tang. Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5642.

APA, Harvard, Vancouver, ISO, and other styles

21

Fleischli, Christoph, Dominique Sirena, Guillaume Lesage, Menzo J. E. Havenga, Roberto Cattaneo, Urs F. Greber, and Silvio Hemmi. "Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor." Journal of General Virology 88, no. 11 (November 1, 2007): 2925–34. http://dx.doi.org/10.1099/vir.0.83142-0.

Full text

Abstract:

We recently characterized the domains of the human cofactor protein CD46 involved in binding species B2 adenovirus (Ad) serotype 35. Here, the CD46 binding determinants are mapped for the species B1 Ad serotypes 3 and 7 and for the species B2 Ad11. Ad3, 7 and 11 bound and transduced CD46-positive rodent BHK cells at levels similar to Ad35. By using antibody-blocking experiments, hybrid CD46–CD4 receptor constructs and CD46 single point mutants, it is shown that Ad3, 7 and 11 share many of the Ad35-binding features on CD46. Both CD46 short consensus repeat domains SCR I and SCR II were necessary and sufficient for optimal binding and transgene expression, provided that they were positioned at an appropriate distance from the cell membrane. Similar to Ad35, most of the putative binding residues of Ad3, 7 and 11 were located on the same glycan-free, solvent-exposed face of the SCR I or SCR II domains, largely overlapping with the binding surface of the recently solved fiber knob Ad11–SCR I–II three-dimensional structure. Differences between species B1 and B2 Ads were documented with competition experiments based on anti-CD46 antibodies directed against epitopes flanking the putative Ad-binding sites, and with competition experiments based on soluble CD46 protein. It is concluded that the B1 and B2 species of Ad engage CD46 through similar binding surfaces.

APA, Harvard, Vancouver, ISO, and other styles

22

Daniele, Patrick, Carla Mamolo, Joseph C. Cappelleri, Timothy Bell, Alexander Neuhof, Gabriel Tremblay, Mihaela Musat, and Anna Forsythe. "Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma." PLOS ONE 17, no. 5 (May 12, 2022): e0267979. http://dx.doi.org/10.1371/journal.pone.0267979.

Full text

Abstract:

Progression-free survival (PFS) is a common primary endpoint in newly diagnosed multiple myeloma (NDMM). Patients with NDMM typically have longer PFS and are more likely to achieve minimal residual disease (MRD) or complete response (CR) compared to patients with relapsed or refractory multiple myeloma. Response-based surrogate endpoints may hold value given the longer follow-up time required to evaluate PFS in NDMM. In this work, systematic literature reviews of Medline, Embase, and Cochrane databases (2010-06/2020) and relevant congresses (2018–2020) were performed to identify randomized clinical trials (RCTs) and real-world studies in NDMM reporting median PFS and objective response. Associations between PFS and each response endpoint were evaluated using Pearson’s product-moment correlation weighted by sample size in each RCT arm. Unadjusted and adjusted weighted linear regression models were applied to estimate the gain in median PFS associated with each response endpoint. Statistically significant correlations were identified for median PFS with overall response rate (ORR; Pearson r = 0.59), CR (r = 0.48), stringent CR (sCR; r = 0.68), and MRD (r = 0.69). The unadjusted models estimated 0.50 (95% CI: 0.36, 0.64; p<0.001), 0.42 (95% CI: 0.25, 0.58; p<0.001), 1.05 (95% CI: 0.58, 1.52; p<0.001), and 0.35 (95% CI: 0.12, 0.58; p = 0.006) months of median PFS gained per point of ORR, CR, sCR, and MRD, respectively. Associations for median PFS remained statistically significant in models adjusted for age and treatment type with ORR (0.35, 95% CI: 0.21, 0.49; p<0.001), and adjusted for age and International Staging System risk stage with CR (0.29, 95% CI: 0.16, 0.41; p<0.001). Due to small sample size, adjusted models could not be constructed for sCR or MRD. Nevertheless, evidence of significant survival benefit (p<0.05) associated with MRD negativity and sCR was identified across real-world studies. These findings provide support for the use of response outcomes as surrogate endpoints to estimate PFS benefit in NDMM.

APA, Harvard, Vancouver, ISO, and other styles

23

Siniatchkin, M., W.-D. Gerber, P. Kropp, T. Voznesenskaya, and AM Vein. "Are the Periodic Changes of Neurophysiological Parameters During the Pain-Free Interval in Migraine Related to Abnormal Orienting Activity?" Cephalalgia 20, no. 1 (February 2000): 20–29. http://dx.doi.org/10.1046/j.1468-2982.2000.00002.x.

Full text

Abstract:

Objective and methods Migraine patients are characterized by increased amplitude and reduced habituation of contingent negative variation (CNV). Furthermore, the CNV underlies periodic changes during the pain-free interval, being maximal before attack. The periodicity of CNV is related to periodic changes in habituation, probably due to variation of orienting activity during the pain-free interval. CNV and orienting response (OR) were studied in 20 females suffering from migraine without aura and in 12 matched healthy females. The neurophysiological recordings in the group of patients were performed 1–4 days before and 4 days after a migraine attack. The amplitudes and habituation of early and late components and total CNV were calculated. The OR was assessed using the habituation of the skin conductance response (SCR) and alpha blocking (AB). The non-parametric tests were employed for statistical analysis. Results There were no differences between the two groups for habituation of all CNV components and of SCR following an attack. However, the habituation of AB was significantly reduced in migraine. Before attack we observed a significantly reduced habituation of the early and total CNV and of the AB compared to controls and recordings performed after an attack. The habituation of the late component and of SCR remained unchanged. Conclusions The abnormal habituation could be explained by the periodic changes of physiological parameters during the pain-free interval. The impaired habituation of early CNV in migraine is associated with increased orienting activity seen only in the central component (AB) of OR.

APA, Harvard, Vancouver, ISO, and other styles

24

Kapoor, P., S. Kumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, F. K. Buadi, D. Dingli, P. R. Greipp, S. V. Rajkumar, and M. A. Gertz. "Prognostic value of stringent complete response (sCR) post-autologous stem cell transplant (SCT) in multiple myeloma (MM)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 8587. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.8587.

Full text

Abstract:

8587 Background: The measurement of serum immunoglobulin free light chains (FLC) has diagnostic and prognostic utility in MM. Normalization of the FLC ratio may define a deeper complete response after therapy than by standard criteria of CR. A sCR requires normalization of the FLC ratio and absence of clonal plasma cells in the bone marrow (BM) in addition to the standard criteria for CR. The objective of our study was to evaluate the impact of specific types of CR [sCR, CR or near CR (nCR/ immunofixation positive CR)] post-SCT on time to progression (TTP) and overall survival (OS). Methods: 468 MM patients who had achieved at least a partial response post-SCT were studied. The results of serum and urine protein studies, serum FLC assay, and BM evaluation, including measurement of marrow plasma cell clonality by immunohistochemistry obtained ≥60 days after SCT were used to determine the best response. TTP was defined as the time from SCT to progression, with non-myeloma related deaths censored. Results: 179 patients achieved varying degrees of CR as their best response. 39, 35 and 105 patients achieved nCR, CR and sCR, respectively. The median estimated follow-up for the entire cohort was 52 months from the diagnosis and 41 months from SCT. The median TTP was 15, 29 and 35 months for patients achieving nCR, CR and sCR, respectively (P<0.0001). The median OS for patients achieving nCR was 53 months from the diagnosis, but not reached for those with a CR or sCR (P=0.0009). The 5-year OS was 80% and 79% for patients with CR and sCR, respectively (P=NS). Similarly, OS from SCT was significantly shorter in patients achieving nCR (42 months vs. not reached for patients in CR and sCR; P<0.001). Conclusions: Achievement of a sCR represents a deeper response state compared to conventional CR, translating to a longer response duration post SCT, validating its inclusion in the modified uniform response criteria. While we did not see a significant improvement in OS with sCR compared to CR in this group, this question needs to be addressed in a larger study. The step wise improvement in the response duration across nCR, CR and sCR highlights the contribution of immunofixation studies, marrow assessment of clonality and FLC estimates. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

25

Nagaraju, Ganesh, Andrea Hartlerode, Amy Kwok, Gurushankar Chandramouly, and Ralph Scully. "XRCC2 and XRCC3 Regulate the Balance between Short- and Long-Tract Gene Conversions between Sister Chromatids." Molecular and Cellular Biology 29, no. 15 (May 26, 2009): 4283–94. http://dx.doi.org/10.1128/mcb.01406-08.

Full text

Abstract:

ABSTRACT Sister chromatid recombination (SCR) is a potentially error-free pathway for the repair of DNA lesions associated with replication and is thought to be important for suppressing genomic instability. The mechanisms regulating the initiation and termination of SCR in mammalian cells are poorly understood. Previous work has implicated all the Rad51 paralogs in the initiation of gene conversion and the Rad51C/XRCC3 complex in its termination. Here, we show that hamster cells deficient in the Rad51 paralog XRCC2, a component of the Rad51B/Rad51C/Rad51D/XRCC2 complex, reveal a bias in favor of long-tract gene conversion (LTGC) during SCR. This defect is corrected by expression of wild-type XRCC2 and also by XRCC2 mutants defective in ATP binding and hydrolysis. In contrast, XRCC3-mediated homologous recombination and suppression of LTGC are dependent on ATP binding and hydrolysis. These results reveal an unexpectedly general role for Rad51 paralogs in the control of the termination of gene conversion between sister chromatids.

APA, Harvard, Vancouver, ISO, and other styles

26

Hopkins, Robert. "Forecasting consumer demand in free markets: Business use of skin conductance response (SCR)." International Journal of Psychophysiology 11, no. 1 (July 1991): 40. http://dx.doi.org/10.1016/0167-8760(91)90171-s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Czikhardt, Richard, Hans van der Marel, and Juraj Papco. "GECORIS: An Open-Source Toolbox for Analyzing Time Series of Corner Reflectors in InSAR Geodesy." Remote Sensing 13, no. 5 (March 2, 2021): 926. http://dx.doi.org/10.3390/rs13050926.

Full text

Abstract:

Artificial radar reflectors, such as corner reflectors or transponders, are commonly used for radiometric and geometric Synthetic Aperture Radar (SAR) sensor calibration, SAR interferometry (InSAR) applications over areas with few natural coherent scatterers, and InSAR datum connection and geodetic integration. Despite the current abundance of regular SAR time series, no free and open-source software (FOSS) dedicated to analyzing SAR time series of artificial radar reflectors exists. In this paper, we present a FOSS Python toolbox for efficient and automatic estimation of: (i) the clutter level of a particular site before a corner reflector installation, (ii) the Radar Cross Section (RCS) to track a corner reflector’s performance and detect outliers, for example, due to damage or debris accumulation, (iii) the Signal-to-Clutter Ratio (SCR) to predict the positioning precision and the InSAR phase variance, (iv) the InSAR displacement time series of a corner reflector network. We use the toolbox to analyze Sentinel-1 SAR time series of the network of 23 corner reflectors for InSAR monitoring of landslides in Slovakia.

APA, Harvard, Vancouver, ISO, and other styles

28

Johnston, Amilynne. "Soapbox Rebellion: The Hobo Orator Union and the Free Speech Fights of the Industrial Workers of the World, 1909–1916 by Matthew S. May." South Central Review 36, no. 1 (2019): 129–31. http://dx.doi.org/10.1353/scr.2019.0006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Daibog, E. I., K. Kecskemety, Yu I. Logachev, and G. M. Surova. "The rigidity dependence of characteristic decay time and mean free path in SCR events." Cosmic Research 48, no. 6 (December 2010): 501–8. http://dx.doi.org/10.1134/s001095251006002x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Voorhees, Peter M., Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J. Costa, Yana Lutska, Padma Bobba, et al. "Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN." Blood Advances 5, no. 4 (February 19, 2021): 1092–96. http://dx.doi.org/10.1182/bloodadvances.2020003642.

Full text

Abstract:

Abstract The phase 2 GRIFFIN study of daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) for transplant-eligible, newly diagnosed multiple myeloma included a safety run-in phase followed by a randomized phase. The ongoing randomized phase has met its prespecified primary end point of an improved stringent complete response (sCR) rate after consolidation for D-RVd (reported elsewhere). Final analysis of the safety run-in cohort is reported herein and provides longer follow-up (median, 40.8 months) encompassing daratumumab plus lenalidomide (D-R) maintenance therapy. Patients in the safety run-in cohort (N = 16) received 4 induction cycles (D-RVd), high-dose melphalan supported by autologous stem cell transplant, 2 consolidation cycles (D-RVd), and 24 months of maintenance (D-R). By the end of consolidation, all patients had responded, with a best response of sCR in 9 (56.3%) patients; 8 (50.0%) patients were minimal residual disease (MRD) negative (10‒5 threshold). After maintenance, 15 (93.8%) patients had achieved a best response of sCR, and 13 (81.3%) patients were MRD (10‒5) negative. Estimated 36-month progression-free and overall survival rates were 78.1% and 93.8%, respectively. One death from progressive disease occurred in the patient who did not achieve sCR. Observed safety profiles were consistent with daratumumab and RVd. With >3 years of median follow-up, D-RVd achieved durable responses that deepened with D-R maintenance. This study was registered at www.clinicaltrials.gov as #NCT02874742.

APA, Harvard, Vancouver, ISO, and other styles

31

Lannes, Xavier, Aurélien Traverso, Charline Coron, William G. Blakeney, and Stefan Bauer. "Partial Rotator Cuff Repair With Biceps Rerouting and Double Tenodesis: An Efficient and Cost-Effective Biological Superior Capsular Reconstruction." Video Journal of Sports Medicine 1, no. 4 (July 2021): 263502542110164. http://dx.doi.org/10.1177/26350254211016469.

Full text

Abstract:

Background: Chronic rotator cuff tears (RCTs) are common and are often only partially repairable. Surgical treatment is challenging in younger patients. Surgical options include partial repair, tendon transfer, subacromial spacer, superior capsular reconstruction (SCR), and reverse shoulder arthroplasty. The use of SCR has been expanded and commercialized. The proposed techniques are complex using free avascular grafts and up to 7 anchors with associated increase in theater time and nonrefunded cost. Biceps SCR has shown promising biomechanical resistance and seems to offer a simple and cost-effective alternative. Indications: Patients with RCTs (Goutallier stage ≥3, Patte 3) without arthritis that are at least partially repairable (infraspinatus and subscapularis) are candidates. Patients with mechanically intact long head of biceps (LHB) and superior labrum anterior to posterior (SLAP) anchor (minimal fraying of <10% and fraying of SLAP without full-thickness tears acceptable) are also candidates. Technique: Key steps include arthroscopic release/lateral opening of the bicipital grove (15-20 mm) and placement of a first footprint anchor 8 to 10 mm posterior to the anatomical sulcus. Use of a 5-mm burr to create a new rerouting groove obliquely from the first anchor to the original groove, 15 to 20 mm caudal to the summit of the tubercle. Lasso-loop translation and tenodesis of the LHB to the first anchor. Use of a second caudal biceps tenodesis anchor with lasso-loops at the caudal end of the new groove. These 2 anchors create a rerouting bipedicle tenodesis performing the function of both an SCR and biceps tenodesis. Single-row, tension-free over-the-top repair of infraspinatus and the bursal layer of supraspinatus is completed with a third anchor on the rerouted biceps which remains in continuity. Results: The pilot series (n = 10) with a mean follow-up of 12 months (9-18 months) shows satisfactory outcomes. One patient developed a postoperative frozen shoulder and one a secondary Popeye deformity. Functional scores and patient satisfaction improved in all cases. The subjective shoulder value improved from a mean of 30% (10%-40%) preoperatively to 75% (60%-80%) postoperatively and the constant score from 30 points (20-40) to 68 points (60-71). Conclusion: As long as LHB and its SLAP anchor are adequate, biceps rerouting in combination with partial rotator cuff repair is a safe alternative to time-consuming and expensive commercialized SCR techniques.

APA, Harvard, Vancouver, ISO, and other styles

32

Xia, Lei, Hanqing Xuan, Yang Cao, Zhebin Du, Hai Zhong, and Qi Chen. "Computational Analysis of Influencing Factors and Multiple Scoring Systems of Stone Clearance Rate after Flexible Ureteroscopic Lithotripsy." Computational Intelligence and Neuroscience 2022 (September 26, 2022): 1–8. http://dx.doi.org/10.1155/2022/7879819.

Full text

Abstract:

Our research aims at the analysis of various stone scoring systems which are referred to as STONE scoring system (SSS) in this study. GUY’s scoring system and RUSS scoring system (RSS) are utilized to predict stone-free status (SFS) after surgery and problems after percutaneous nephrolithotomy (PCNL) for harder stones. The data of 68 patients with renal calculi who received FURL in Ren Ji Hospital from Jan 2020 to Mar 2021 are collected as the study subjects. There were 44 male and 24 female patients, with an average age of 55.6 ± 11.4 years. Reliability analysis of related influencing factors (IF) of stone clearance rate (SCR) and multiple scoring systems after flexible ureteroscopic lithotripsy (FURL) was performed. Relevant factors with statistical significance for postoperative SCR were selected for logistic regression analysis (RA). According to the SSS score, GSS classification, and RUSS score, the SCR after FURL was statistically analyzed. The results showed that the P values corresponding to stone position (lower caliceal), cumulative stone diameter (CSD), urinary tract infection, and external physical vibration lithecbole (EPVL) were less than 0.05. The area under the ROC curve of RUSS score, SSS score, and GSS grading was 0.932, 0.841, and 0.533, respectively. The main IF of SCR after FURL were stone location (lower caliceal), CSD, urinary tract infection, and EPVL. The RUSS score system was the best in the evaluation of SCR after FURL. In the previous research, the score systems such as CROES (CRS), SSS, S-ReS, C, and GSS for the prediction of SFS were compared. In our analysis, we have compared the RUSS scoring system which has proven to be giving better results as compared to SSS and GSS. We also performed the regression analysis and found that the stone location shows the strongest correlation of all the other factors for stone clearing rate.

APA, Harvard, Vancouver, ISO, and other styles

33

Nadiminti, Kalyan, Kamal Kant Singh Abbi, Annick Tricot, Allyson Schultz, Lindsay Dozeman, Sarah L. Mott, Fenghuang Zhan, and Guido J. Tricot. "Bortezomib, Dexamethasone, Thalidomide and Melphalan (VDT-Mel) Preparative Regimen in Autologous Stem Cell Transplant (ASCT) Results in a Very High Stringent CR (sCR) Rate in Multiple Myeloma (MM)." Blood 126, no. 23 (December 3, 2015): 1971. http://dx.doi.org/10.1182/blood.v126.23.1971.1971.

Full text

Abstract:

Abstract Background: Melphalan 200mg/m2 is the standard preparative regimen in MM and addition of other cytotoxic drugs has not been found to result in superior activity. The novel agents have improved outcome in MM significantly, but data on their role in preparative regimens are scarce. The purpose of this study was to understand the toxicity and efficacy of triple therapy with VDT in combination with high-dose melphalan. Methods: An IRB approved retrospective analysis was performed on all patients who received an ASCT with the VDT-Mel during 2012-2014. Mel: 100 mg/m2 was given on days -4 and -1; V: 1 mg/m2 on days -4, -1, +2 and +5; T: 100 mg daily from -5 to +5; and D: 20 mg/day from -4 to -1 and +2 to +5. End points were treatment-related toxicity during the first 100 days and quality of response at 6 months post-transplant; 98 patients had follow-up ≥ 6 months. Patients in sCR were also minimal residual disease negative (MRD-) by 10-color flow cytometry with a sensitivity of 10-4. Results: 100 patients received 153 transplants; 47 patients underwent single and 53 had tandem transplants (TT); 64 patients received early (≤ 12 months of induction therapy) and 36 salvage transplantation. Median age was 61 y; median followup was 16.2 months. Only 1patient had achieved a sCR and 11 a CR prior to transplantation. Best responses at 6 months were 53% sCR (and MRD-), 24% CR, and 9% VGPR. The sCR rate after single transplant was 47% (overall) and 54% (early transplant) vs 59% and 60% after TT. Grade 3-5 non-hematologic toxicities were almost entirely related to infections (38% and 53% in single and TT, respectively); the 100-day mortality rate was 2.6% (4/153), 1.8% for early transplants and 4.5% for salvage transplants. Median time to ANC recovery > 500/µL was 12 days in both early and salvage transplantation. Conclusion: VDT-Mel is well-tolerated and resulted in minimal additional toxicity and a similar mortality rate when compared to historic data of MEL alone. Importantly, the sCR rate with MRD- by flow cytometry at 6 months in our study was very high compared to published reports. The ultimate sCR rate will be higher as at this time an additional 13 patients attained a sCR during further follow up past 6 months for a total of 66% sCR. Since both sCR and MRD- are proven early surrogate markers for progression-free and overall survival, it appears highly likely that this regimen will be superior to Mel alone and should become the new standard for ASCT in myeloma. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

34

Koulieris, Efstathios, Dimitrios Maltezas, Nikolaou Eytychia, Vassiliki Bartzis, Tatianna Tzenou, Vassiliki Karali, Pessach Ilias, et al. "Impact of Novel M-Component Based Biomarkers On to Progression Free Survival After Treatment in Intact Immunoglobulin Multiple Myeloma." Blood 120, no. 21 (November 16, 2012): 2927. http://dx.doi.org/10.1182/blood.v120.21.2927.2927.

Full text

Abstract:

Abstract Abstract 2927 Background and Aims: Multiple Myeloma (MM) is characterized by bone marrow (BM) plasma cell infiltration and the presence of serum/urine monoclonal immunoglobulin (Ig). The depth of response has been associated with longer PFS in MM causing subsequent prolonged survival. Recently novel M-based biomarker immunoassays have been developed (Freelite™, Hevylite™) and their significance in MM diagnosis and prognosis has been demonstrated.1,2 Furthermore serum Free Light Chains (sFLC) are used for better assessment of treatment response, thus patients are considered to achieve stringed Complete Response (sCR) by having CR criteria plus normal serum Free Light Chains Ratio (sFLCR) and absent clonal cells on BM.3 The significance of Hevylite™ on response has not been assessed so far. Patients in nCR or better do not automatically restore their ratio of intact monoclonal Ig/intact polyclonal Ig of the same class (Hevylite™ or HLCR). We therefore investigated the importance of sFLCR and HLCR normalisation at plateau on PFS, in a series of patients with intact Ig MM. Patients and Methods: 50 intact immunoglobulin MM patients were studied from diagnosis to last follow up. Immunofixation was IgG (26 -kappa and 12 –lamdba) and IgA (6 –kappa and 6 -lambda). All patients were symptomatic at diagnosis. Sera samples (n=312) were analyzed for sFLC-kappa and sFLC-lambda with Freelite™ and sFLCR were calculated, and for IgGkappa, IgGlambda IgAkappa, IgAlambda with Hevylite™ and ratios IgGkappa/IgGlambda, IgGlambda/IgGkappa, IgAkappa,/IgAlambda and IgAlambda/IgAkappa (HLCRs) were calculated. sFLCRs and HLCRs values above the 95%-ile of normal individuals were considered abnormal. Statistical analysis was performed using SPSS ver 15.0. File data were reviewed. Results: At diagnosis sFLCR was abnormal in 86% of patients while HLCR was abnormal in all. All treatment lines were initiated according to standard criteria and median lines of therapy were 2 (range 1–11). Median follow up was 33 months (7–145). During patients' cumulative follow-up, 145 lines of therapy were studied and the subsequent responses were estimated. Thirty eight percent of responses were sCR, CR and nCR, 20% PR, 18% MR and 24% refractory and progressive disease. HLCR normalized in 44% of patients with sCR, CR and nCR. The depth of response correlated to PFS and patients in sCR, CR and nCR had longer PFS than the others (p<0.001). Serum FLCR and HLCR normal values at response were both strong parameters of increased PFS after treatment at any line (p=0.035 and p=0.046 respectively). Conclusion: Serum HLCR normalization at plateau reflects prolonged responses in intact Ig MM. Disclosures: Harding: Binding Site: Employment. Bradwell:The Binding Site: shareholder Other.

APA, Harvard, Vancouver, ISO, and other styles

35

Nitoi, Luciana Carmen, Valeriu Ardeleanu, Anca Pantea Stoian, and Lavinia Alexandra Moroianu. "Correlation Between Body Composition Analysis and Biochemical Nutritional Markers in Maintenance Hemodialysis Patients with Chronic Liver Disease." Revista de Chimie 71, no. 11 (December 4, 2020): 94–100. http://dx.doi.org/10.37358/rc.20.11.8378.

Full text

Abstract:

Several approaches have been used to assess protein-energy wasting syndrome, such as clinical evaluation, biochemical nutritional markers, anthropometric measurements, but Bioelectrical Impedance Analysis (BIA) techniques hold a central place in clinical settings. The aim of this study is to report our clinical experience with BIA and the correlations between biochemical nutritional markers and BIA nutritional parameters in hemodialysis (HD) patients associating or free of chronic liver disease. This cross-sectional observational study included 69 HD patients divided into two groups: 33 with chronic liver disease (CLD+) versus 36 chronic liver disease-free (CLD-) from one HD unit in Romania. Serum albumin (SA), serum creatinine (SCr) and C-reactive protein (CRP) were obtained from the HD arterial line immediately before the HD session and by BIA the body composition including total body water (TBW), total body fat (TBF), lean fat free mass(LFFM), body muscular mass (BMM), malnutrition index and body protein reserve (PR) were assessed. No significant differences between groups were found in BCM, BMM, PR and TBF (p = 0.92, p = 0.60, p = 0.907, and p = 0.634, respectively). Malnutrition index had a significantly higher mean value in HD-CLD(+) patients (p = 0.00). HD-CLD(-) group showed a strong correlation between SA and SCr and BCM, BMM (kg), LFFM (kg) and body PR (kg) (r=.48, r=.50, r=.44, r=.50; resp. r=.42, r=.40, r=.36, r=.42). In HD-CLD(+) patients, a significant positive correlation was found between SA and SCr and LFFM and body PR (r=.37, r=.35; resp. r=.44, r=.35). Discussion: BIA is one of the most accurate techniques for assessing nutritional status and should be regularly used in clinical practice along with biochemical nutritional markers in HD patients. Although the protein metabolism depends to a large extent on liver function, CLD cannot be considered as having a significant impact on nutritional status in HD patients.

APA, Harvard, Vancouver, ISO, and other styles

36

Alsaad, K., N. Oudah, A. Al Ameer, K. Fakeeh, A. Al Jomaih, and A. Al Sayyari. "Glomerulonephritis with Crescents in Children: Etiology and Predictors of Renal Outcome." ISRN Pediatrics 2011 (October 30, 2011): 1–5. http://dx.doi.org/10.5402/2011/507298.

Full text

Abstract:

Objective. To investigate the clinicopathological features and outcome of glomerulonephritis with crescents among Saudi children. Method. This is a retrospective study of cases of crescentic glomerulonephritis (CrGN) seen over a 9-year period. Histological features and renal function were recorded. Results. Thirty-seven cases were enrolled. The mean percent of glomeruli with crescents was 39% (±19). Lupus nephritis (LN) was the commonest etiology (54.1%). At presentation, the serum creatinine (SCr) was 218.2 (±174.3) umol/l, and 57.1% of the cases had nephrotic range proteinuria. By the end of the observation period, SCr dropped to 81.0 (±67.7) umol/l (P=0.001). Worsening renal function was associated with younger age (P=0.002), non-LN etiology (P=0.01), more crescents (P=0.019), and ATN (P=0.05). At the end of the followup, more patients in the LN group were dialysis-free (P=0.017) and had improved renal function (0.01) than in the non-LN group. Using multivariate analysis, the only independent factor found to predict need for dialysis or change in SCr level was percent of globally sclerosed glomeruli (P=0.034). Conclusion. LN is the main cause of CrGN in our cohort of children. The LN group had less globally sclerorsed glomeruli and better renal prognosis than the non-LN group.

APA, Harvard, Vancouver, ISO, and other styles

37

Wang, Huimin, Ping Ning, Yaqing Zhang, Yanping Ma, Jifeng Wang, Lanying Wang, and Qiulin Zhang. "Highly efficient WO3-FeO catalysts synthesized using a novel solvent-free method for NH3-SCR." Journal of Hazardous Materials 388 (April 2020): 121812. http://dx.doi.org/10.1016/j.jhazmat.2019.121812.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Sazama, Petr, Lukasz Mokrzycki, Blanka Wichterlova, Alena Vondrova, Radim Pilar, Jiri Dedecek, Stepan Sklenak, and Edyta Tabor. "Unprecedented propane–SCR-NO x activity over template-free synthesized Al-rich Co-BEA ∗ zeolite." Journal of Catalysis 332 (December 2015): 201–11. http://dx.doi.org/10.1016/j.jcat.2015.10.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Mejía-Centeno, Isidro, Salvador Castillo, Roberto Camposeco, and Gustavo A. Fuentes. "SCR of NOx by NH3 over model catalysts: The kinetic data-linear free energy relation." Catalysis Communications 31 (January 2013): 11–15. http://dx.doi.org/10.1016/j.catcom.2012.10.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Dehghani, Mohammad Hadi, Ali Reza Mesdaghinia, Simin Nasseri, Amir Hossein Mahvi, and Kamal Azam. "Application of SCR Technology for Degradation of Reactive Yellow Dye in Aqueous Solution." Water Quality Research Journal 43, no. 2-3 (May 1, 2008): 183–87. http://dx.doi.org/10.2166/wqrj.2008.021.

Full text

Abstract:

Abstract The effect of sonochemical reactors (SCR) technology upon the degradation of reactive yellow dye has been studied and reported here. Sonochemical reactors (ultrasound irradiation) produce strong cavitation in aqueous solution causing shock wave and reactive free radicals by the violent collapse of the cavitation bubble. These effects should contribute to destruction as well as the decomposition of dyes. This research investigated the efficacy of sonochemical reactors for decolourizing reactive yellow dyes in aqueous solution. In this research, the influence of concentration, frequency, treatment time, and reactor power on the dye decomposition were investigated. The results obtained from the study carried out have shown that SCR can be used effectively for degradation of reactive yellow dyes. The results suggested sonochemical reactors provided maximum destruction, and 120 min treatment time at 130 kHz and 500 W were the most effective for the maximum degradation of reactive yellow dye.

APA, Harvard, Vancouver, ISO, and other styles

41

Hong, Chi-Cherng, Tim Li, LinHo, and Jong-Seong Kug. "Asymmetry of the Indian Ocean Dipole. Part I: Observational Analysis." Journal of Climate 21, no. 18 (September 2008): 4834–48. http://dx.doi.org/10.1175/2008jcli2222.1.

Full text

Abstract:

The physical mechanism for the amplitude asymmetry of SST anomalies (SSTA) between the positive and negative phases of the Indian Ocean dipole (IOD) is investigated, using Simple Ocean Data Assimilation (SODA) and NCAR–NCEP data. It is found that a strong negative skewness appears in the IOD east pole (IODE) in the mature phase [September–November (SON)], while the skewness in the IOD west pole is insignificant. Thus, the IOD asymmetry is primarily caused by the negative skewness in IODE. A mixed-layer heat budget analysis indicates that the following two air–sea feedback processes are responsible for the negative skewness. The first is attributed to the asymmetry of the wind stress–ocean advection–SST feedback. During the IOD developing stage [June–September (JJAS)], the ocean linear advection tends to enhance the mixed-layer temperature tendency, while nonlinear advection tends to cool the ocean in both the positive and negative events, thus contributing to the negative skewness in IODE. The second process is attributed to the asymmetry of the SST–cloud–radiation (SCR) feedback. For a positive IODE, the negative SCR feedback continues with the increase of warm SSTA. For a negative IODE, the same negative SCR feedback works when the amplitude of SSTA is small. After reaching a critical value, the cold SSTA may completely suppress the mean convection and lead to cloud free conditions; a further drop of the cold SSTA does not lead to additional thermal damping so that the cold SSTA may grow faster. A wind–evaporation–SST feedback may further amplify the asymmetry induced by the aforementioned nonlinear advection and SCR feedback processes.

APA, Harvard, Vancouver, ISO, and other styles

42

Jakubowiak, Andrzej J., Kent A. Griffith, Dominik Dytfeld, David H. Vesole, Sundar Jagannath, Tara B. Anderson, Brian K. Nordgren, et al. "Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX)." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 8011. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8011.

Full text

Abstract:

8011 Background: Combination treatment (tx) with CFZ, LEN, and DEX (CRd) is well tolerated and highly active in NDMM. In a phase 1/2 study, CRd provided rapid reduction of disease by 68% after cycle (C) 1 and 94% ≥partial response (PR) at a median of 8C, including 65% ≥very good PR and 53% ≥near CR (nCR), which improved to 79% ≥nCR after C12 (ASH 2011, Abstr 631). Here, we examine the clinical significance of the response rates with longer follow-up. Methods: Pts with NDMM were treated in 28-day (d) C with CFZ 20–36 mg/m2 IV (d1, 2, 8, 9, 15, 16), LEN 25 mg PO (d1–21) and DEX 40/20 mg PO weekly (C1–4/5–8). After C4, autologous stem cell transplant (ASCT) candidates achieving ≥PR could collect stem cells but then continued CRd with the option to proceed to ASCT. After C8, pts received CRd maintenance, using the last tolerated doses, with LEN/DEX at the same schedule but a modified CFZ schedule (d1, 2, 15, 16). Response was assessed by IMWG criteria plus nCR. Results: As of Nov 30, 2011, median follow-up was 14 mo (range 4–25) with 33/53 (62%) pts achieving ≥nCR and 42% sCR. After a median of 13C (range 1–25), 36 pts completed C8 and continued CRd maintenance, 64% achieving sCR. 20/22 pts in CR evaluated for minimal residual disease (MRD) by multiparameter flow cytometry had no MRD. Progression-free survival (PFS) rate was 97% at 12 and 92% at 24 mo. All pts who achieved sCR have maintained response for a median of 9 mo (range 1–20). Extended CRd tx was well tolerated. During CRd maintenance, the most common toxicities (all grades) were lymphopenia (30%), leukopenia (26%), and fatigue (25%), and peripheral neuropathy remained limited (11%, all G1/2). There were no tx discontinuations due to toxicity during maintenance and limited dose modifications (CFZ 19%, LEN 28%, DEX 31%). Conclusions: CRd is highly active in NDMM, providing rapid and deep responses. Extended tx was well tolerated and resulted in improved depth of response with a high sCR rate and a significant proportion of pts without evidence of MRD. Responses were durable with very promising PFS. All pts who achieved sCR remained on CRd with sustained sCR. These results compare favorably to other frontline regimens.

APA, Harvard, Vancouver, ISO, and other styles

43

Vickers, Richard, Sumita Chowdhury, and Mark Wilcox. "1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial." Open Forum Infectious Diseases 5, suppl_1 (November 2018): S411. http://dx.doi.org/10.1093/ofid/ofy210.1175.

Full text

Abstract:

Abstract Background Diagnosis of CDI includes fecal detection of a C. difficile toxigenic strain (TS) or free toxins (FT). TS detection does not distinguish infection from colonization. Guidelines recommend an FT test be part of diagnostic algorithms. Here we report outcome differences, based on diagnostic method at enrollment, from a Phase 2 clinical trial of RDZ, a novel CDI antibiotic designed to treat CDI and reduce recurrence of CDI (rCDI). Methods This double-blind study randomized 100 patients 1:1 to 10 days RDZ 200 mg BID or vancomycin (VAN) 125 mg QID treatment. Subjects were enrolled with CDI symptoms and a positive diagnostic result (FT or TS). Baseline (BL) stool samples were assessed for the presence of FT. All subjects entered the intent to treat (ITT) population; those subjects positive for FT entered a modified ITT (mITT), the primary analysis population. Primary endpoint was sustained clinical response (SCR) defined as cure at end of therapy and no rCDI for the next 30 days. rCDI was defined as CDI symptoms, a positive diagnostic test and need for therapy; a sensitivity analysis considered positive FT rCDI cases. BL fecal concentrations of lactoferrin and calprotectin were determined by enzyme immunoassay. Results Of 100 subjects enrolled, 69 (36 RDZ: 33 VAN) were FT positive at BL. RDZ compared with VAN recipients had improved SCR rates via reduced rCDI. Absolute differences in SCR between RDZ and VAN (prespecified 90% CI) for MITT (FT positive) and ITT subjects were 24.3% (3.1, 39.1) and 14.0% (−1.8, 28.8), respectively. Absolute SCR differences between the MITT and ITT subjects from the sensitivity analysis were 26.2% (4.6, 40.6) and 14.3% (−1.7, 29.1). Median BL calprotectin and lactoferrin levels (µg/mL) were significantly higher for FT positive subjects at 1,002 and 87, than for FT negative subjects at 53 and 4, respectively. Conclusion RDZ showed improved SCR in comparison with VAN. Treatment differences were greater in MITT subjects. Lower SCR improvement in RDZ ITT subjects is likely due to enrollment of some colonized rather than infected subjects; this explanation is supported by higher calprotectin and lactoferrin levels in FT-positive samples. These data demonstrate the importance of FT testing in-line with CDI guideline recommendations. Disclosures R. Vickers, Summit Therapeutics: Employee, Salary and Stock options. S. Chowdhury, Summit Therapeutics: Employee, Salary and Stock options. M. Wilcox, Summit Therapeutics: Consultant, Research Contractor and Scientific. Advisor, Consulting fee, Research grant and Research support.

APA, Harvard, Vancouver, ISO, and other styles

44

Aguayo, J., A. Teplick, A. Butturini, A. Erdreich-Epstein, R. Jubran, J. Villablanca, D. Hyder, B. Britt, and J. Finlay. "Factors affecting event free survival (EFS) after high dose chemotherapy with stem cell rescue (HDC/SCR) in children with brain tumors." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 9057. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.9057.

Full text

Abstract:

9057 Background: HDC/SCR is a novel approach for treatment of children with brain tumors. Despite several studies suggesting results are better in children with primitive neural ectodermal tumors (PNET) or medulloblastoma (MB), it is controversial whether other factors can predict outcome. Methods: We retrospectively analyzed data from 53 patients who underwent HDC/SCR for brain tumors at Children Hospital Los Angeles between June 1992 and June 2005. Patients were aged 4 months to 15.8 years at diagnosis and 9 months to 18.1 years at transplant. In all cases the conditioning regimen included thiotepa and/or etoposide and/or carboplatin. The variables considered were age at diagnosis, histology, extent of disease, conditioning regimen, radiation therapy, stem cell type and timing of transplant. Results: Diagnoses included 33 PNET/MB, 8 high-grade gliomas, 5 ependymomas, 3 germinomas, 2 choroid plexus carcinomas and 2 rhabdoid tumors. Overall event free survival at 36 months was 53±9.1% in PNET/MB and 40±15.5% in tumors with other histology. Variables associated with better EFS in PNET/MB were no prior progression (p=0.00094), no spread into bone marrow (p=1.2 E-10) and age less than 3 years at diagnosis (p=0.046). There was a trend toward improved outcome if there was gross total resection of the tumor (p=0.11). Patients with PNET transplanted before progression had better EFS if they had localized disease at diagnosis (p=0.00024), and if gross total surgical resection was accomplished (p=0.11). Patients with PNET/MB transplanted after progression had better EFS if there was no spread of disease into blood or bone marrow (p=0.00023), if they were male (p=0.053), had localized disease at relapse (p=0.12) and if radiotherapy was given after transplant (p=0.053). In patients with tumors of other histology, the only variable associated with prolonged EFS was gross total resection (p=0.026). Conclusions: Children most likely to benefit from HDC/SCR for brain tumors are those less than 3 years old who are newly diagnosed with PNET that is locally confined, and those with a non-PNET diagnosis who have gross total resection of tumor. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

45

Jasielec, Jagoda K., Tadeusz Kubicki, Noopur Raje, Ravi Vij, Donna Reece, Jesus Berdeja, Benjamin A. Derman, et al. "Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma." Blood 136, no. 22 (November 26, 2020): 2513–23. http://dx.doi.org/10.1182/blood.2020007522.

Full text

Abstract:

Abstract In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4 cycles of KRd induction, ASCT, 4 cycles of KRd consolidation, and 10 cycles of KRd maintenance. The primary end point was rate of stringent complete response (sCR) after 8 cycles of KRd with a predefined threshold of ≥50% to support further study. Seventy-six patients were enrolled with a median age of 59 years (range, 40-76 years), and 35.5% had high-risk cytogenetics. The primary end point was met, with an sCR rate of 60% after 8 cycles. Depth of response improved over time. On intent-to-treat (ITT), the sCR rate reached 76%. The rate of minimal residual disease (MRD) negativity using modified ITT was 70% according to next-generation sequencing (<10−5 sensitivity). After median follow-up of 56 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 72% and 84% for ITT, 85% and 91% for MRD-negative patients, and 57% and 72% for patients with high-risk cytogenetics. For high-risk patients who were MRD negative, 5-year rates were 77% and 81%. Grade 3 to 4 adverse events included neutropenia (34%), lymphopenia (32%), infection (22%), and cardiac events (3%). There was no grade 3 to 4 peripheral neuropathy. Patients with NDMM treated with KRd with ASCT achieved high rates of sCR and MRD-negative disease at the end of KRd consolidation. Extended KRd maintenance after consolidation contributed to deepening of responses and likely to prolonged PFS and OS. Safety and tolerability were manageable. This trial was registered at www.clinicaltrials.gov as #NCT01816971.

APA, Harvard, Vancouver, ISO, and other styles

46

Zang, Rongyu, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, et al. "A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 6001. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6001.

Full text

Abstract:

6001 Background: In China, secondary cytoreductive surgery (SCR) has been standard of care in some high volume cancer centers for ovarian cancer (OC) and most pts prefer surgery over the past two decades. Although GOG213 showed no OS benefit, the debate on selected pts and the conflict with certain local clinical care is still open. Methods: Pts with 1st relapsed OC after 6m+ platinum-free interval (PFI) were eligible if predicted to be a potential R0 by iMODEL score combined with PET-CT image and were randomized to SCR followed by chemotherapy (surgery arm) vs 2nd line chemotherapy alone (no surgery arm). Co-primary endpoint is PFS and OS. The 2nd endpoint is accumulated treatment-free survival (TFSa), which was defined as the overall survival time minus the time of surgery and chemotherapy after randomization. We report analysis of PFS and interim analysis of TFSa. Results: 357 pts were randomized 2012-2019. 6.3% of 175 pts were operated in no surgery arm and cross-over rate was 36.9% in 2nd+ relapsed pts of no surgery arm. 97% and 96% of pts received a platinum-containing 2nd line therapy. Complete resection (R0) rate was 76.7% in overall and 61.1% in pts with iMODEL> 4.7. 60 d mortality rates were 0 % in both surgery and no surgery arm. Postoperative 30 d complication rate with ≥ grade 3 was 5.2%. The median follow-up was 36.0 m. Median PFS was 17.4 m and 11.9 m in surgery and no surgery arm, respectively (HR 0.58, 95% CI 0.45-0.74, p < 0.001). Median time to start of first subsequent therapy (TFST) was 18.1 m vs 13.6 m in favor of the surgery arm (HR 0.59, 95%CI 0.46-0.76). 1.1% and 10.1% of pts underwent Bevacizumab and PARPi maintenance in the 2nd line therapy. The OS and TFSa was immatured. The median TFSa was unreached and 39.5 m in R0 subgroup and no surgery arm, respectively (HR0.59, 95%CI 0.38-0.91). TFSa in surgery arm showed a better long-term survival than that in no surgery group (restricted mean survival time from 60 to 72m: 6.2m vs 4.2m). Conclusions: SCR in selected pts resulted in a dramatically significant extension of PFS. The interim analysis of TFSa indicate that SCR might contribute to long-term survival.

APA, Harvard, Vancouver, ISO, and other styles

47

Wang, Yong, Toshiki Nishitoba, Yunan Wang, Xiangju Meng, Feng-Shou Xiao, Weiping Zhang, Bernd Marler, et al. "Cu-Exchanged CHA-Type Zeolite from Organic Template-Free Synthesis: An Effective Catalyst for NH3-SCR." Industrial & Engineering Chemistry Research 59, no. 16 (March 17, 2020): 7375–82. http://dx.doi.org/10.1021/acs.iecr.9b06708.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Mikkilineni, Lekha, Elisabet E. Manasanch, Danielle Natrakul, Jennifer N. Brudno, Jennifer Mann, Stephanie L. Goff, James C. Yang, et al. "Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity." Blood 138, Supplement 1 (November 5, 2021): 3837. http://dx.doi.org/10.1182/blood-2021-152688.

Full text

Abstract:

Abstract Multiple myeloma (MM) is a malignancy of plasma cells that is nearly always incurable. T cells expressing chimeric antigen receptors (CAR) that target B-cell maturation antigen (BCMA) can recognize and eliminate MM. The murine or other non-human sequences in the single-chain variable fragments (scFv) of many anti-BCMA CARs can elicit recipient immune responses against CAR T cells. We constructed a CAR incorporating an anti-BCMA fully-human heavy-chain variable domain designated FHVH33. FHVH33 lacks the light chain, the artificial linker sequence, and the 2 linker-associated junctions of a scFv, so FHVH33 is smaller than a scFv and is likely to be less immunogenic. The FHVH33-containing CAR utilized in this clinical trial also incorporated a CD8a hinge and transmembrane domain, a 4-1BB domain, and a CD3z domain. The CAR was designated FHVH33-CD8BBZ and was encoded by a gamma-retroviral vector. T cells expressing FHVH33-CD8BBZ were designated FHVH33-T. The FHVH33-T production process was initiated with unsorted peripheral blood mononuclear cells and took 7 days. The treatment protocol was 300 mg/m 2 of cyclophosphamide and 30 mg/m 2 of fludarabine on days -5 to -3 followed by infusion of FHVH33-T on day 0. Twenty-five patients received FHVH33-T infusions. Median age of the treated patients was 62 (range 39-73). Patients received a median of 6 prior lines of therapy (range 3-10). Five dose levels were assessed (Table). Dose level 4, 6x10 6 CAR + T cells/kg was identified as the maximum feasible dose after considering efficacy and manufacturing factors. Twenty-three of 25 patients (92%) obtained objective responses (OR) of partial response (PR) or better. Seventeen patients (68%) attained a best response of stringent complete response (sCR) or very good partial response (VGPR). Thirteen patients have ongoing responses. To date, the median duration of response is 50 weeks for the highest two dose levels. At present, the overall median progression free survival (PFS) is 78 weeks; as responses are ongoing in 13 patients (52%), PFS will likely improve. Nine of 25 patients had extramedullary plasmacytomas at baseline; patients with extramedullary plasmacytomas at baseline were less likely to achieve sCR (P=0.011). All 25 treated patients were evaluable for toxicity. Eighteen patients had grade 1 or 2 cytokine-release syndrome (CRS), and 6 patients had grade 3 CRS. One patient had no CRS. No patients had grade 4 CRS. Five patients received tocilizumab and 4 patients received corticosteroids for CRS. Two of twenty-five patients had grade 3 neurological toxicity possibly attributable to FHVH33-T. No patient had grade 4 neurologic toxicity attributable to CAR T cells. One patient died of influenza pneumonia. We assessed blood CAR+ cells by quantitative PCR. The median peak blood CAR+ cell level was 126.5 cells/µl (range 3-1071 cells/µl), and the median time post-infusion of peak blood CAR + cell levels was 10.5 days (range 7-14). Peak CAR T-cell level was not associated with obtaining a sCR. In contrast, blood CAR+ T cell levels at both 1 and 2 months after infusion were statistically higher for patients obtaining sCR. For the 1-month time-point, blood CAR+ cell levels in cells/mL were 20 for sCR patients and 4 for not sCR patients (P=0.04). Pretreatment serum BCMA was not statistically different when patients obtaining or not obtaining sCR were compared (median serum BCMA in pg/mL: sCR patients 86,243; not sCR patients 261,675, P=0.20). We assessed cell-surface BCMA expression level on MM cells by antibody binding capacity (ABC) flow cytometry. Cell-surface BCMA expression level was not statistically different in sCR versus not sCR patients (median ABC in sites/cell: sCR patients 844; not sCR patients 535, P=0.29). Patients with MM expressing low levels of BCMA obtained durable responses of greater than 2 years duration, which suggests that FHVH33-T can recognize low levels of cell-surface BCMA. Eight patients had extramedullary plasmacytomas at relapse; 4 patients had plasmacytomas biopsied. Two of the biopsied plasmacytomas were BCMA+, and two were BCMA-negative by immunohistochemistry. FHVH33-CD8BBZ CAR T cells caused relatively mild toxicity and a high rate of sCRs in patients with relapsed MM including MM with low cell-surface BCMA expression. Figure 1 Figure 1. Disclosures Brudno: Kyverna Therapeutics: Membership on an entity's Board of Directors or advisory committees. Lam: Kite, a Gilead Company: Patents & Royalties. Kochenderfer: Kite, a Gilead Company: Patents & Royalties: on anti-CD19 CARs, Research Funding; Bristol Myers Squibb: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

49

Wang, Juan, Linying Wang, Dali Zhu, Wenhao Cui, Peng Tian, and Zhongmin Liu. "One-pot synthesis of Na+-free Cu-SSZ-13 and its application in the NH3–SCR reaction." Chemical Communications 57, no. 40 (2021): 4898–901. http://dx.doi.org/10.1039/d1cc00966d.

Full text

Abstract:

Na⁺-free Cu-SSZ-13 zeolites have been rationally synthesized via a cooperative strategy, which has the advantages of rapid crystallization (9–48 h), high yield (86–94%) and adjustable Cu content.

APA, Harvard, Vancouver, ISO, and other styles

50

Glavey, Siobhan V., Angela Dispenzieri, Morie A. Gertz, Shaji Kumar, Martha Q. Lacy, Francis K. Buadi, S. Vincent Rajkumar, et al. "The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL Amyloidosis." Blood 118, no. 21 (November 18, 2011): 2868. http://dx.doi.org/10.1182/blood.v118.21.2868.2868.

Full text

Abstract:

Abstract Abstract 2868 Introduction: Improvement in renal parameters is fundamental for the assessment of organ response to treatment in immunoglobulin light chain amyloidosis (AL). Renal response, defined as a >50% reduction in proteinuria with <25% decrease in renal function, is associated with superior overall survival (OS); however, a systematic study of the interplay of proteinuria, creatinine, and free light chain has not been performed. The intent of this study is to better understand the components of the renal response criteria. Methods: Patients who underwent autologous stem cell transplantation from 1995 to 2010 were eligible for this retrospective analysis if they had > 1 year of follow-up and a baseline 24 hour urine protein > 1 g/d. Those who were dialysis dependent or died before 1 year were excluded as not evaluable for renal response. Results: Of the 435 patients screened, 152 met criteria. On univariate analysis, >50% proteinuria reduction (p < 0.001), serum free light chain (sFLC) reduction by >50% (p = 0.002), <25% increase in serum creatinine (Scr) (p = 0.0003), and a 50% proteinuria reduction within 15 months of treatment (p = 0.04) were associated with better OS. Multivariate analysis using a proportional hazard model showed that sFLC reduction by >50% (0.006), <25% increase in serum creatinine (Scr) (p = 0.0005) and >50% proteinuria reduction (p = 0.0006) were independently associated with OS. In addition, OS was significantly better among patients achieving >85% reduction in proteinuria than those with < 85% but >50%, p = 0.03 (Figure 1). Patients with >75% reduction in sFLC were more likely to achieve >50% proteinuria reduction (p = 0.009). Most importantly, among those with > 25% increase in Scr, only those patients who had <85% proteinuria reduction had a worse OS (Figure 2a, p = 0.006). There was no difference in OS among those with >85% proteinuria reduction and a rise in Scr of > 25% (Figure 2b, p = 0.77). Conclusion: Renal response is an excellent prognostic marker in patients with AL. This is the first study to show the depth of renal response correlates with OS. Patients who had the highest levels of proteinuria reduction (> 85%) had a significantly better OS than those with >50% but <85%. We also found that the negative impact of >25% decrease in renal function was only pertinent in those who did not have >85% reduction in proteinuria. These findings should help better refine the definition of renal response criteria in AL patients. Disclosures: Leung: Binding Site: Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'SCR free'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles